Supplements

Chromium: disputed essentiality, chromium III versus VI, old intake tables, diabetes guidance, weight-loss evidence, and supplement safety

6 sources · Latest source check 2026-10-13 UTC

On this page

Chromium’s essential-nutrient status is disputed. US reference tables reflect a 2001 assessment, while EFSA concluded in 2014 that evidence did not establish a dietary requirement. NIH describes the disagreement. An intake table cannot establish that everyone has a clinically measurable chromium requirement.[1]

Chemical form matters

Chemical form matters
Term	Meaning
Chromium III / trivalent	The form discussed in nutrition and supplements.[1]
Chromium VI / hexavalent	A different toxic industrial-exposure form.[1]
Picolinate / chloride	Different supplemental compounds, usually supplying chromium III.[2]

Food chromium measurements vary with the source and process

NIH describes chromium in several foods, with amounts affected by soil, irrigation water, animal feed and transfer from stainless-steel processing equipment. A precise-looking food table therefore does not erase uncertainty about the actual amount in a particular serving. It also does not establish that eating more of one ingredient prevents diabetes.[2]

A supplement form and its clinical effect are separate issues

Chromium picolinate and chloride are supplement forms. Their names do not establish clinical benefits. A trial of one compound in a selected population cannot establish effects for every chromium product.[2]

The US table has a stated historical basis

NIH explains that the US Food and Nutrition Board set adequate intakes from usual intake patterns in 2001 and has not reevaluated chromium since then. Those values remain visible in factsheets, alongside the essentiality debate. The presence of a published number and the date of the underlying assessment both matter when interpreting what the table can establish.[1]

An early nutrition-support observation is not a complete requirement calculation

EFSA reviewed reports of improvement after chromium supplementation in people receiving total parenteral nutrition. It judged these among the more suggestive observations but found inadequate information about reversibility and dose-response to identify a human dietary requirement. A striking case report and a validated population requirement are different forms of evidence.[3]

No validated deficiency target means consumer testing claims need care

NIH states that no validated method determines chromium nutritional status and no clinically defined chromium-deficiency state exists. Urinary chromium can track recent absorption without reliably representing body stores. A low-looking hair, urine or blood result should not be turned into a deficiency diagnosis or a supplement target merely because the laboratory reports a numerical value.[1]

A proposed insulin mechanism is not proof of benefit in healthy people

EFSA did not find evidence of a beneficial intake effect in healthy subjects sufficient to set a reference value. Its conclusion concerns the essentiality and requirement question. It should neither be broadened into a claim that no study can ever show a disease-specific effect nor narrowed into a reason to advertise routine healthy-person chromium optimization.[3]

The 2026 ADA recommendation does not endorse chromium for glycemic benefit

Recommendation 5.16 in the ADA’s 2026 Standards asks clinicians to assess supplement intake and does not recommend micronutrient supplementation, including chromium, for glycemic benefits. This is current disease-specific guidance from that edition, rather than a recommendation inferred from the old US intake table. The recommendation’s evidence category is ADA’s, not a new Atlas grade.[4]

A treatment recommendation considers more than whether a small trial changed one glucose measurement. Clinical usefulness, consistency, safety and the applicable population matter. This article inspected the recommendation and selected explanatory passages; it did not independently appraise every cited diabetes trial or establish that a product can replace prescribed treatment.[4]

An older review found a small signal with low confidence

Cochrane’s 2013 review included nine trials and 622 adults with overweight or obesity, followed for eight to twenty-four weeks. Pooled weight loss was about one kilogram greater with chromium picolinate than placebo. The authors judged the evidence low quality and could not establish a reliable relationship between higher doses and greater benefit. Its search ended in December 2012.[5]

Only three trials reported adverse-event information, and studies did not report important clinical-event, quality-of-life or long-term outcomes. The review therefore cannot certify long-term safety or meaningful health improvement from the small average weight difference. It is a dated synthesis, rather than a complete appraisal of research published through 2026.[5]

PCOS findings do not settle a hormone-treatment claim

NIH describes mixed findings in polycystic ovary syndrome and, where possible benefits appeared, small effects. A marketed “hormone balance” claim is broader than a measured short-term endpoint in a selected study. Fertility, symptoms, metabolic risk and adverse effects require their own outcomes and cannot be inferred from one changed laboratory measurement.[2]

A medicine review needs the actual supplement exposure

Chromium supplements can interact with medicines. Unconfirmed deficiency does not justify ignoring medications or increasing intake. The compound, amount, other ingredients and clinical context matter. An ingredient-level study does not certify an entire multi-ingredient glucose or weight-loss product.[2]

A toxicity claim needs the chemical form and exposure route

ATSDR’s older ToxFAQs distinguishes metallic chromium, chromiumIII and chromiumVI, and relates hazards to form, dose, duration and exposure route. Workplace inhalation and ingestion of high chromiumVI levels are not interchangeable with dietary chromiumIII exposure. The sheet also uses older essential-nutrient terminology; that wording does not resolve the essentiality dispute discussed above or establish a clinical benefit from supplements.[6]

Evidence & uncertainty

EFSA found the proposed essential metabolic role unsubstantiated and did not consider an adequate intake appropriate. This does not mean every pharmacological research question has been answered. Essentiality, a possible treatment effect and the safety of a supplement are separate questions that need different evidence.[3]

Selected-source overview · Independent review pending

Published questions

Is chromium’s essential-nutrient status settled simply because an old US intake table exists?

Selected-source overview · Independent review pending. Read the evidence context.

NIH and EFSA describe evidence that challenges that interpretation.[1]

Evidence behind this answer

Chromium: Health Professional Fact Sheet
agency condition or prevention explanation · Date not stated
Selected relevant original official page passages inspected · Chemical species, disputed essentiality, 2001 assessment and unvalidated status testing